Scynexis, Inc. develops therapies for severe rare diseases, focusing on addressing unmet medical needs. The company is advancing SCY-770, a direct AMPK activator for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD), and SCY-247, a second-generation fungicide targeting antimicrobial-resistant fungal infections. Scynexis operates in the biopharmaceutical sector, primarily serving patients with progressive and underserved conditions.
- Website
- www.scynexis.com
- Issuer profile
- All listings